10 Analysts Have This to Say About Kinnate Biopharma
Portfolio Pulse from Benzinga Insights
In the last quarter, Kinnate Biopharma (NASDAQ:KNTE) received 6 bullish, 2 somewhat bullish, and 2 indifferent analyst ratings. The average 12-month price target is $21.04, down 8.52% from the previous average of $23.00.
June 08, 2023 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kinnate Biopharma received mostly positive analyst ratings in the last quarter, with an average 12-month price target of $21.04, down 8.52% from the previous average.
The majority of analyst ratings for Kinnate Biopharma are bullish or somewhat bullish, indicating a positive outlook for the stock. However, the decrease in the average 12-month price target suggests that analysts may have slightly lowered their expectations for the stock's performance. This could lead to a short-term increase in the stock price, but with a lower potential upside.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100